Scientific Sessions 2027
Abstract Submission Guidelines

Table of Contents

Key Dates.....2

Abstract Submission Requirements.....2-3

Scientific Sessions Portal.....3

Abstract Character Guidelines.....3-4

Abstract Structure and Formatting Guidelines.....4-5

Abstract Writing Standards.....5

Abstract Selection Process.....5-6

Embargo Policy.....6-8

Abstract Publication, Revisions, and Withdrawals.....8

Program Information.....8-9

Abstract Presenter Expenses/Meeting Registration Fee.....9

Travel Grants.....9

Step-by-Step Abstract Submission Instructions.....10-13

Technical Support.....13

Key Dates for the 2027 Scientific Sessions Abstract Program

Monday, September 28, 2026	Abstract submission opens
Tuesday, January 5, 2027, 5:00 PM ET	Abstract submission deadline (no extensions)
Tuesday, March 2, 2027	Acceptance status and Copyright Transfer Agreement notifications emailed to presenting authors
Tuesday, March 9, 2027	Abstract withdrawal deadline/Copyright Transfer Agreement must be completed by presenting author
Friday, June 11, 2027	The embargoed text of most abstracts will be made available in the mobile app for attendee planning purposes
June 18-21, 2027	2027 Scientific Sessions in Washington, DC

The American Diabetes Association's® 2027 Scientific Sessions is scheduled to take place in Washington, DC, June 18-21, 2027 at the Walter E. Washington Convention Center. **All presenters will be required to attend in-person to make their abstract presentations.** It is **strongly encouraged** that you begin the visa process as soon as possible to avoid delays. See our **Travel & Transportation Information page** for a visa letter of invitation and additional information.

Abstract Submission Requirements

- Abstracts for the American Diabetes Association's® 2027 Scientific Sessions must be submitted online via the **Scientific Sessions Portal**. Emails and word processing files submitted outside the abstract submission site will not be accepted.

- A fee of $90.00 (USD) must be paid for each abstract submitted. The fee covers costs associated with the submission, review, and programming processes. This fee is charged regardless of whether or not the abstract is accepted for presentation and/or publication. **Submission fees will not be refunded.**

  Payment must be made by credit card. Major credit cards (American Express, Visa, MasterCard, and Discover) are accepted for the secure online payment.

- An abstract **is not** eligible for submission if it has been presented at another national or international meeting or will be published prior to the 2027 Scientific Sessions, June 18-21, 2027. Failure to notify the Association of such publication or presentation will result in a moratorium on the submission of abstracts for all authors in question for two years.

- There is no limit to the number of abstracts an author may submit; however, **an author may only serve as the presenting author on two submissions**. It is the author's responsibility to designate a new presenter for presentation conflicts that arise. If accepted, the presenter **must** be a co-author listed on the abstract at the time of submission. **Authors cannot be added to the abstract after the January 5, 2027, 5:00pm ET deadline**.

- All presenting author changes must be submitted via email to abstracts@diabetes.org no later than May 18, 2027.

- Abstracts must have a complete status by January 5, 2027, 5:00 PM ET, or the abstract will not be considered for the Scientific Sessions program. **Extensions will not be granted.**

- The abstract submission site allows a maximum of 30 authors to be added to each submission.

- All authors listed on the abstract must update their disclosure in the **Portal** for the 2027 meeting. **Authors should enter their disclosure as soon as possible to avoid delays.** Any author who has a "Not Current" disclosure status on the submission will cause the abstract to not be complete. Authors will not be added to the submission after January 5, 2027 at 5:00 PM ET. If you cannot locate an author to add them to an abstract submission, please confirm they have created an **ADA account** and have finalized their disclosure.

Types of Submissions Not Accepted

The following are types of submissions that ADA typically does **not** accept. An abstract that does not present results of a study or states "results will be discussed at the Scientific Sessions" is not acceptable.

- Case Studies
- Case Reports
- Study Designs
- Literature Reviews – An abstract fully based on a review article would not be eligible.

Scientific Sessions Portal

This time-saving system eliminates the process of re-entering contact information and disclosures for authors listed on more than one abstract. All abstract authors are responsible for entering their disclosure into the **Portal** **once** per meeting.

Authors who have previously participated in other ADA activities or registered for Scientific Sessions in the past may already have an **ADA Account**. Those authors must log into the Portal to finalize their disclosure for the 2027 meeting **BEFORE** you add their name to the author list.

Authors who do not already have an **ADA Account** must create a new account. Once the ADA Account has been created, the author will need to log into the **Submission Portal** to finalize their disclosure**. The submission site will not allow you to add an author who does not have an ADA account.**

Submitters are responsible for confirming all authors are added to the submission and have a current disclosure status before the January 5, 2027, 5:00 PM ET deadline. Additional authors will not be added after the submission deadline.

See the **Step-by-Step Portal Instructions** section for instructions on how to use the Portal.

Abstract Character Guidelines

Abstracts are limited to 1,800 characters (about 250 words). Spaces do not count as characters. Tables must be uploaded as image files. The file for Figures and Tables must be provided during submission at a sufficiently high resolution (minimum 1,000 pixels width/height, or a resolution of 300 dpi or higher). Files should be uploaded as jpeg files. **Do not upload PDF or Word documents**. All Figures and Tables should have a short explanatory title and caption.

Counts toward character limit:

- Abstract Title (Character limit including spaces 200)
- Text in abstract body
- Graphics – Addition of an image whether a figure or table deducts 500 characters each
- Section Headers in the submission site – 51 characters have been added to not impact the 1,800 character limit

Does not count toward character limit:

- Names of authors in the author block (Do not add them to the abstract body)
- Spaces in the abstract body
- Caption of graphic (if added to the image file)

Abstract Structure and Formatting Guidelines

Abstracts should be structured and organized as an **Introduction & Objective**, **Methods**, **Results** and **Conclusion**. Each text box in the submission site is labeled with these section headers. Please make sure to copy your abstract text into the correct text box. Do not place the entire abstract body text into the Introduction and Objective text box.

- **Introduction and Objective:** The abstract should begin with a sentence or two explaining the clinical (or other) importance of the study question. This section should also state the precise objective or study question addressed in the project (e.g., "To determine whether…"). If possible, use the PICO format for the objective (https://www.nlm.nih.gov/oet/ed/pubmed/pubmed_in_ebp/02-100.html). The objective is different than the background or introduction. Authors are advised not to have a long introduction under this section (up to 3 sentences is sufficient).

- **Methods:** Methods should be concise and include the epidemiological design, patient selection (key inclusion/exclusion criteria), description of independent and dependent variables, and the most important statistical test.

- **Results:** This section should describe baseline characteristics of participants followed by primary and secondary outcomes. Report estimates of associations including appropriate measures of variability and uncertainty (e.g., odds ratios with confidence intervals). If authors are including tables/figures, please avoid duplicating information that is provided in the table/figures.

- **Conclusion:** This section should provide only findings of the study directly supported by the objective results. Authors may state its clinical or future research implications. Please avoid speculation and over-generalization. Give equal emphasis to positive and negative findings of equal scientific merit.

Abstract Writing Standards

- Abstracts must be written in English.
- **Do not** enter author information into the abstract body. Doing so negates a blind review.
- **Do not** begin sentences with numerals.
- **Do not** include the abstract title, references, or grant support in the abstract body.
- Standard abbreviations may be used without definition. Nonstandard abbreviations must be placed in parentheses after the first use of the abbreviation.
- Use generic drug names. If it is necessary to use a trade name, then those of several companies must be used.
- When submitting your abstract, the ADA recommends using language that is neutral, nonjudgmental, and free from stigma when referring to a person with diabetes. For example, referring to the person with diabetes as a person with diabetes, not as a diabetic as this may be interpreted as negative, blaming, or fault finding.
- Proofread abstracts carefully to avoid errors. Changes/modifications **will not be allowed after the January 5, 2027, 5:00 PM ET deadline**. This includes typographical errors. Changes/modifications to submissions (including adding or removing authors) after the submission deadline is not possible. Your abstract, if selected, will be published exactly as submitted.

Note: The Association may modify the format to fit the look and feel of the media on which it is displayed or distributed.

Abstract Selection Process

All abstracts successfully submitted are peer-reviewed through a blind review process.

Originality of work, adequacy of data, and clarity of exposition are the determinants in the selection of abstracts. An abstract that does not present the results of the study will not be accepted.

The final decision with respect to selection, programming, and/or publication of any abstract will be made by the Association's Scientific Sessions Meeting Planning Committee.

Abstracts submitted during the regular submission period may be selected for **oral presentation**, **poster presentation**, **ePoster Theater presentation**, **published only**, or **not selected**. Abstracts selected for oral presentation, poster presentation, ePoster Theater presentation and published only will be published on the journal *Diabetes*® website. Abstracts selected as Published Only **will not** be presented at the 2027 Scientific Sessions.

Abstract acceptance status will be sent via email to the designated **presenting author** in early-March. Make sure the presenting author has their email setting to allow correspondence from abstracts@diabetes.org. All correspondence will be with the presenting author chosen at the time of submission. To change the presenting author, the author must be listed on the abstract submission by the submission deadline, January 5, 2027 at 5:00 pm ET. Adding/removing authors will not be possible

after the submission deadline. Presenting author change requests must be submitted to abstracts@diabetes.org no later than May 18, 2027.

Embargo Policy

All meeting attendees, members of the media, companies, institutions, organizations, universities, investment advisors, and all other individuals are required to abide by the embargo policy governing the American Diabetes Association's (ADA's) Scientific Sessions.

An embargo means that the scientific findings and results contained in any abstract or in any Late Breaking Trial accepted for presentation through the Scientific Sessions Program Planning Committee, are confidential and may not be announced, publicized, disclosed, or distributed before the applicable embargo date and time.

The acceptance of an abstract or Late Breaking Trial for presentation at the Scientific Sessions may be publicly disclosed; however, the scientific findings and results remain subject to embargo until the applicable embargo date and time.

This policy applies to all formats of release, including the Scientific Sessions online itinerary planner, meeting app, press materials, investor communications, websites, social media, news releases, and any other distribution method.

The purpose of the embargo policy is to protect the scientific integrity and novelty of the research presented at the ADA's Scientific Sessions. All presentations and submissions are considered preliminary until the time of presentation or otherwise authorized for public release by the ADA.

Violation of the embargo policy by release of information prior to its embargoed date and time will result in removal of the individual, as well as the affiliated company, institution, organization, or other entity, from the Scientific Sessions and will result in a two-year ban on participation in ADA Scientific Sessions activities.

Prior Publication and Presentation:

If an abstract is also submitted as a manuscript for publication, authors are responsible for coordinating publication to align with the ADA's embargo policy.

Abstracts submitted to the ADA's Scientific Sessions may not have been previously presented at another major national or international scientific, biomedical, or medical meeting prior to their presentation at the ADA's Scientific Sessions, unless expressly approved by the ADA. Likewise, abstracts accepted for presentation at the ADA's Scientific Sessions may not be presented at another major scientific, biomedical, or medical conference before their ADA presentation unless expressly approved by the ADA.

Authors are responsible for promptly notifying the ADA of any publication or presentation conflicts. Failure to notify the ADA will result in withdrawal of the abstract and a two-year moratorium on abstract submissions for all authors involved.

The ADA will not adjust embargo times to accommodate journal publication schedules or presentation dates at another scientific meeting.

Late-Breaking Trial Symposia

Late-Breaking Trial symposium proposals are accepted into the Scientific Sessions program through review by the Scientific Sessions Program Planning Committee and are distinct from the abstract submission process.

Abstracts submitted to the Scientific Sessions are expected to contain sufficient results to permit scientific peer review and evaluation. Because Late Breaking Trial proposals may be considered before final study results are available, they are reviewed separately from the abstract submission process.

Acceptance of a Late Breaking Trial symposium by the Scientific Sessions Program Planning Committee serves as the basis for inclusion in the Scientific Sessions program, and the ADA's Scientific Sessions embargo policy applies.

Scientific findings and results associated with accepted Late-Breaking Trial symposia are embargoed from the time of acceptance into the Scientific Sessions program until the scheduled start of the symposium, unless otherwise authorized by the ADA.

Specific Embargo Dates and Times:

- **Oral Presentations:** Abstracts selected for oral presentation, are embargoed from the time of submission until the scheduled start of their presentation at the ADA's Scientific Sessions. The ADA reserves the right to adjust the embargo as needed.
- **Poster Presentations (including Late Breaking Posters):** Abstracts or clinical trial results selected for poster presentation are embargoed from the time of submission until **Friday, June 18, 2027 at 6:30 PM ET.**
- **Symposia (Including Late-Breaking Trials):** Scientific findings and results are embargoed until the scheduled start of the specific symposium.
- **Published Only:** Abstracts selected for Published Only are embargoed from the time of submission until **Friday, June 18, 2027 at 10:30 AM ET.**

Regular and Late Breaking Abstract Availability
The embargoed text of most of the abstracts will be made available in the mobile app on Friday, June 11, 2027. By accessing the abstracts through the mobile app, you agree to abide by the embargo policy.

Note: The abstract embargo still applies; however, abstracts are made available to attendees to assist in creating their itineraries for the meeting. **Not all abstracts will be available to view as some will follow the Press Program Abstract Availability timeline (see below).*

ADA Scientific Press Program Abstract Availability
Certain abstracts and Late-Breaking Trial symposia may be selected for inclusion in the ADA's official Scientific Press Program. Content selected for the Press Program will not be published in the mobile app ahead of the published embargo time.

Abstract Publication
Abstracts will be published online in a supplement to the journal *Diabetes®* at the end of each day they are presented.

Exception to Embargo Policy—Publicly Traded Companies:
Industry announcements required by the Security Exchange Commission must be approved by the ADA prior to release, and any level of information released without that ADA's approval will be considered a violation of the embargo policy. Please send announcements for review and approval to SciSessionsPress@diabetes.org; a five-business day turnaround time is needed.

Questions regarding embargo dates, embargo exceptions, or other aspects of the ADA Scientific Sessions embargo policy may be directed to **abstracts@diabetes.org and/or SciSessionsPress@diabetes.org**.

Abstract Publication, Revisions, and Withdrawals

- The submission of an abstract grants ADA the rights to publish the abstract on the journal *Diabetes*® website or in other publications produced by ADA. All abstracts accepted for the Scientific Sessions will be published on the journal *Diabetes*® website, unless withdrawn by the withdrawal deadline.

- Abstracts may be revised online until January 5, 2027, 5:00 PM ET. Additional Authors and Modifications will **not** be allowed after the submission deadline.

- Abstracts must be withdrawn no later than **March 10, 2027,** or they will be published on the journal *Diabetes*® website. To withdraw an abstract, the presenting author must complete an **Abstract Withdrawal Form** and return it to the ADA by email. Only the presenting author can withdraw the abstract. The abstract processing fee will not be refunded.

Program Information

- **Note**: Presenting authors will not be allowed to reschedule their presentation time(s).

- **Oral Presentation:** Oral presentations are 15 minutes in length. Those selected for an oral presentation will receive their presentation details (date/time) in their acceptance letter.

- **Poster Presentation:** All Posters must be displayed for **all four days** (Friday, Saturday, Sunday, and Monday) in the Poster Hall. The presenting author must be available on their assigned General Poster Session presentation day(s) to answer questions from attendees. Those accepted for a poster presentation will receive their presentation details (date/time) in their acceptance letter. All poster presenters will be given the opportunity to also upload an ePoster (electronic poster) that will be available OnDemand. *Please note: The ePoster does not take the place of the printed poster.*

    - **ePoster Theater Presentations:** Poster presenters will share their research and highlight novel or recent advancements in 8-minute presentation (including Question and Discussion period) with a session moderator as audience members listen in. It is required that the presenter uploads an ePoster for this presentation. Those accepted for an ePoster Theater Presentation will receive their presentation details (date/time) in their acceptance letter. The ePoster Theater presentation is in addition to the regularly scheduled General Poster Session presentation for that abstract.
        - The Poster Hall will open during the Networking Reception on Friday, June 18th at 6:30 PM ET. Presenters will have the opportunity to hang their posters on Friday before the reception so the poster will be on display.

- **Poster Printing Service:** The ADA offers discounted poster printing through our preferred poster service partner. We recommend poster presenters take advantage of this easy, convenient way to order a printed poster. Posters printed through our preferred poster service partner will be printed and shipped directly to the convention center to pick up. Information for the poster printing website will be emailed to presenting authors of accepted abstracts in early-May. **Note:** Poster printing through our partner is not mandatory.

Abstract Presenter Expenses/Meeting Registration Fee

All presenters will be **required** to attend Scientific Sessions in Washington, DC to make their presentation. Expenses associated with an abstract presentation (e.g., travel, hotel, meals, meeting registration fees, etc.) are the sole responsibility of the presenting author. Presenters must register for the meeting in the appropriate category (Member, Non-Member, Student/Resident/Fellow). **Join/renew** membership to receive member rates.

If you register for the meeting at the early-bird rate and your abstract submission is not accepted for presentation, you may request a full refund of your registration fee until **May 6, 2027**.

Travel Grants

The ADA offers a limited number of travel grants, to eligible, early-career investigators and students whose abstracts are accepted for presentation. Travel Grant applications will be sent through email notification to the presenting author of abstracts accepted for oral or poster presentations in March. An applicant must be the presenting author to apply for a travel grant.

Note: Those who have received a travel grant from the ADA within the past two years (2025 or 2026) are not eligible. *Travel Grants are not available for abstracts accepted during the Late Breaking submission period*. Applicants must not be receiving other ADA travel support or be an industry employee.

Abstract Submitters

To access the abstract submission site, click **"Return to Dashboard"** then select **"Submissions"** from the upper menu on the next page. Select the **+ New** button to begin a new submission and follow the **Step-by-Step Abstract Submission Instructions** below.

Abstract Authors

New for 2027: All authors must have an **ADA Account** (it's free). Please view the step-by-step instructions for assistance with completing your disclosure. Once you have finalized your disclosure, click "Return to Dashboard**"** then logout of the portal.

Please then provide the first name, last name, and email address associated with your disclosure account to the abstract submitter. The submitter will use these fields to search for your name in the database to synchronize your information to the abstract submission.

Important: Participants are expected to provide accurate, truthful, and complete information during the disclosure process. Providing false, misleading, or knowingly inaccurate information may result in disciplinary action, including but not limited to, being prohibited from participating in future meetings.

Step-by-Step Abstract Submission Instructions

- Access the abstract submission site via the **Portal**.
    - Use your ADA account credentials to login or follow the "**Forgot your password?"** steps to reset your password or retrieve your username. Any issues with logging in, please contact membership@diabetes.org.
    - If you do not have an ADA account, click create a new account. Once the account is created, go back to the **Portal** to log in.
- You must complete your disclosure before you will have access to the submission site. See the **Step-by-Step Portal Instructions**.
- To begin a new submission, select the **+ New** button. If you do not see this button, be sure that you have finalized your disclosure record and are in the Submissions area of the Portal. **Note:** The button will not appear until you have updated your disclosures.
- **Terms of Use Agreement:** Read the Terms of Use Agreement thoroughly and click on the check box next to each statement to agree. You must agree to each statement to continue.
- **Abstract Title:** The title should be brief, and clear to give reader an insight into the content of the investigation and should specify the type of research (e.g., randomized trial, case-control study, retrospective study).

Use the following formatting guidelines:

- Enter your title in Title Case.
- Titles should not exceed 200 characters.
- **Do not** use all UPPERCASE characters.
- **Do not** *italicize* the entire title.
- **Do not** include a period at the end of the title.
- Do not enter your name or credentials.

Example: This is a Properly Formatted Abstract Title

If copying and pasting your title into the text boxes, you must paste your title as plain text to avoid errors.

- **Category:** Indicate the category for which you wish to have the abstract reviewed. To ensure that your abstract receives proper consideration, please make certain that the abstract is submitted to the appropriate category. The submitter may not request a category change after the submission deadline.
  *ADA reserves the right to change the abstract category if it is determined there is a more appropriate category for the abstract.
- **Presentation Preference:** All abstracts will be considered first for oral presentation followed by poster presentation. Abstracts not selected for presentation will automatically be considered for published only.

The Scientific Sessions Meeting Planning Committee will consider your presentation preference. Please select one of the following options from the drop-down menu. Your presentation preference is not guaranteed. The Committee reserves the right to make a final decision.

- **Author Information:** The submission site will not allow you to add an author who does not have an ADA account. Authors are responsible for entering their disclosures into the **Portal** **once** per meeting. **Additional authors cannot be added after the January 5, 2027 at 5:00 pm ET deadline.**

    - Authors who have previously participated in the Scientific Sessions may have an account in the ADA database. Those authors must log into the Portal to finalize their disclosure for the 2027 meeting **BEFORE** you add their name to the author list. If an author makes a necessary update to their information in the Portal after you have added their name to the author list, remove the author's name and repeat the Add Author process. Doing so will capture the updated account information.

    - Authors who do not have an **ADA account** will need to create an account, then log back into the **Portal** to finalize their disclosure.

- **Adding Authors:** Select the **"Add Author"** button to search the system. You will search by Email Address (required), Last Name (required), and First Name. When located, click **"Add"** next to the author's name to add the author to the submission.

  Common search issues:
    - Special characters within a name are not always recognized. Please use the American spelling.
    - Please ensure that no excess spacing is entered.
    - The system searches for exact matches on First Name, Last Name, and Email address. If a match is not found, please confirm these fields are correct with the author.
    - Please confirm with the author that they have an **ADA account** and have finalized their disclosure.

  Repeat this step until all authors have been added.

- **Adding a Study Group:** If you have a Study Group to enter for this abstract, select the **"Add a Group"** link and then type the group's name in the text box provided.

  Individual names do not qualify as a group. Do not enter a string of individual author names. **Author names added in this area will be deleted from the submission.**

- **Change who is Presenting:** Select the **"Change who is Presenting"** button to change who is listed as the presenting author. You may only designate one presenting author per abstract. All correspondence regarding abstracts will be sent to the presenting author only. Requests to change presenting authors can be made up until May 18, 2027 and should be sent to abstracts@diabetes.org.

- **Change the Order Author(s) are Listed:** Select the **"Change the Order these Author(s) are Listed"** button to change the order in which authors are listed. To re-arrange the order of your authors, select new place numbers from the drop-down menu for each author.

- **Disclosure Information:** All abstract authors must have a **Current** disclosure status.

- If **Current** appears next to the name of the author nothing further is needed to confirm their disclosure information.
- If **Not Current** or **Not Found** appears next to the name of the author, the disclosure is currently incomplete and needs to be finalized by the author. Please use the **"Send Email"** option to send this author a reminder. Each author must have a Current disclosure status before January 5, 2027, 5:00 PM ET or the abstract will remain incomplete and will not be reviewed. Authors cannot be added to the abstract after the submission deadline. For any issues with adding authors, please **contact us for technical support**.

- **Financial Support:**

  - **ADA Support:** If the research presented in this abstract has been supported, in whole or in part, by a grant from the American Diabetes Association, please select **"Yes"** in the drop-down menu. If yes, provide the ADA grant reference number for the award.

    Example: 7-13-BS-123

  - **Other Grant Support:** If grant acknowledgment is required, enter only the name of the grant provider and reference number.

    Example: National Institutes of Health (A12BC345678)

- **Abstract Body:** You may enter your abstract body by clicking **"Enter Abstract Text."** Enter your abstract text into the appropriate sections. See the **Abstract Character Guidelines** section for additional guidelines.

- **Add an Image:** Click the **"Add an Image"** button to upload an image file. The following guidelines apply:

  - Abstracts can have a maximum of two images. Each image counts as 500 characters. **Do not** combine two images into one upload as this reduces the clarity of the image.
  - Tables must be uploaded as image files.
  - Uploads **must be** high-resolution jpeg files. Do not upload PDF or Word documents.
  - Do not include extra space around the image.

- **Payment:** A fee of $90 (USD) must be paid for each abstract submitted to the American Diabetes Association. The fee covers costs associated with the submission, review, and programming processes. This fee is charged regardless of whether or not the abstract is accepted for presentation and/or publication. **Submission fees will not be refunded.**

  Payment must be made by credit card. Major credit cards (American Express, Visa, MasterCard, and Discover) are accepted for the secured online payment. Purchase orders, checks and/or money orders will not be accepted. All payments must be received by the submission deadline.

  You must fill out all fields on the Payment page and click the **"Save and Continue"** button. Payment will be processed once you click Save and Continue.

- **Review My Work:** Confirm that the status of your abstract says **COMPLETE** before the submission deadline. If you have one or more incomplete steps, your abstract **will not** be reviewed. This is a

preview copy, allowing you to review your abstract and print a copy for your records. You may go back to any section to make edits until the submission deadline. **Editing will not be permitted after the submission deadline on Tuesday, January 5, 2027, 5:00 PM ET.**

  - Select either **"Click here if you would like to have a confirmation of your submission emailed to you**" or **"Click here for a print-friendly version of your submission"** to obtain confirmation of your submission.
  - Select "**Click here to get a payment receipt"** to obtain a copy of your payment receipt.

- **Copyright Transfer Agreement:** If the abstract is selected for publication, a Copyright Transfer Agreement will be sent to the presenting author through an email notification in early-March. The presenting author will be required to agree to the terms of the Copyright Transfer Agreement on behalf of all co-authors designated with an electronic signature. The form must be completed through the email notification no later than March 9, 2027, for the abstract to be included in the program.

Technical Support

For Technical Support with the Submission or Disclosure Sites, contact the cOASIS Helpdesk at **diabetes@support.ctimeetingtech.com** or 217-398-1792 between the hours of 8:00 AM and 5:00 PM (CT) Monday through Friday.

For questions regarding Abstract Submission or Scientific Sessions, contact **abstracts@diabetes.org**.

For log in issues or to reset your password, please contact **membership@diabetes.org**.

For additional Scientific Sessions information, visit **scientificsessions.diabetes.org**.